Ubs Group Ag Kintara Therapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.14 - $6.8 $6,466 - $314,085	46,189 Added 1422.08%	49,437 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.14 - $0.5 $105 - $375	-750 Reduced 18.76%	3,248 $1,000
Q3 2021 Nov 15, 2021	SELL	$0.82 - $2.3 $1,416 - $3,974	-1,728 Reduced 30.18%	3,998 $3,000
Q2 2021 Aug 13, 2021	BUY	$1.26 - $2.4 $1,309 - $2,493	1,039 Added 22.17%	5,726 $13,000
Q1 2021 May 12, 2021	BUY	$1.32 - $2.74 $5,367 - $11,140	4,066 Added 654.75%	4,687 $8,000
Q4 2020 Feb 11, 2021	SELL	$1.26 - $1.72 $5,754 - $7,855	-4,567 Reduced 88.03%	621 $1,000
Q3 2020 Nov 12, 2020	BUY	$0.63 - $1.7 $3,268 - $8,819	5,188 New	5,188 $7,000

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.